Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ENTA

Enanta Pharmaceuticals Inc

Dec 05 • 04:00PM ET

9.47

Dollar change -0.53
Percentage change -5.30	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-6.37	Insider Own	7.13%	Shs Outstand	21.06M	Perf Week	-2.47%
Market Cap	199.44M	Forward P/E	-	EPS next Y	-4.39	Insider Trans	0.00%	Shs Float	19.56M	Perf Month	1.07%
Income	-133.82M	PEG	-	EPS next Q	-1.20	Inst Own	96.66%	Short Float / Ratio	7.70% / 3.24	Perf Quarter	-21.93%
Sales	79.20M	P/S	2.52	EPS this Y	27.09%	Inst Trans	-2.80%	Short Interest	1.51M	Perf Half Y	-63.38%
Book/sh	10.29	P/B	0.92	EPS next Y	5.54%	ROA	-31.47%	Target Price	23.00	Perf Year	-79.07%
Cash/sh	17.56	P/C	0.54	EPS next 5Y	-	ROE	-49.74%	52W Range	8.08 - 62.06	Perf YTD	-79.64%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-33.55%	52W High	-84.74%	Beta	0.46
Dividend %	-	Quick Ratio	6.73	Sales past 5Y	-16.21%	Gross Margin	97.01%	52W Low	17.20%	ATR	0.66
Employees	145	Current Ratio	6.73	Sales Q/Q	-6.82%	Oper. Margin	-173.23%	RSI (14)	50.10	Volatility	6.63% 7.06%
Optionable	Yes	Debt/Eq	1.03	EPS Q/Q	-5.14%	Profit Margin	-168.95%	Rel Volume	0.53	Prev Close	10.00
Shortable	Yes	LT Debt/Eq	0.84	Earnings	Nov 20 AMC	Payout	-	Avg Volume	464.52K	Price	9.47
Recom	2.50	SMA20	3.27%	SMA50	-0.53%	SMA200	-58.84%	Volume	247,890	Change	-5.30%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-09-23	Downgrade	JP Morgan	Neutral → Underweight	$14
Aug-08-23	Downgrade	Jefferies	Buy → Hold	$49 → $18
Dec-09-22	Initiated	H.C. Wainwright	Buy	$56
Jul-06-22	Upgrade	Evercore ISI	In-line → Outperform	$62
Jun-01-22	Upgrade	Evercore ISI	Underperform → In-line	$39
Oct-07-21	Initiated	Jefferies	Buy	$95
Sep-09-21	Initiated	SVB Leerink	Mkt Perform	$55
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral	$55
Nov-24-20	Initiated	Evercore ISI	Underperform	$30
Aug-28-20	Resumed	ROTH Capital	Buy	$104
Aug-26-20	Initiated	Piper Sandler	Overweight	$87
Jul-27-20	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$70
Mar-17-20	Upgrade	Robert W. Baird	Neutral → Outperform	$60
Nov-22-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-26-19	Downgrade	JP Morgan	Neutral → Underweight	$86 → $57
May-24-19	Initiated	Wolfe Research	Outperform	$117
Apr-23-19	Upgrade	Berenberg	Hold → Buy	$80 → $120
Dec-13-18	Initiated	Berenberg	Hold	$80
Jun-06-18	Initiated	ROTH Capital	Buy	$133
Feb-08-18	Downgrade	JP Morgan	Overweight → Neutral

Show Previous Ratings

Nov-27-23 09:55AM	How Much Upside is Left in Enanta Pharmaceuticals (ENTA)? Wall Street Analysts Think 88.23% (Zacks)
Nov-22-23 07:00AM	Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference (Business Wire) -9.83%
Nov-21-23 08:46AM	Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2023 Earnings Call Transcript (Insider Monkey) +11.52%
07:18AM	Q4 2023 Enanta Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-20-23 04:54PM	Enanta Pharmaceuticals Inc (ENTA) Reports Fiscal Q4 and Full-Year Earnings Amid R&D Focus (GuruFocus.com)
04:18PM	Loading…
04:18PM	Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET (Business Wire)
Nov-16-23 11:22PM	MILLENNIUM MANAGEMENT LLC Bolsters Portfolio with Enanta Pharmaceuticals Inc (ENTA) Shares (GuruFocus.com)
Nov-13-23 10:00AM	Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for (Zacks)
07:00AM	Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023 (Business Wire)
Oct-30-23 10:01AM	Alpine Immune Sciences, Inc. (ALPN) Surges 8.9%: Is This an Indication of Further Gains? (Zacks) +5.63%
Oct-13-23 07:00AM	Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline (Business Wire)
Sep-17-23 12:00PM	Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference (Business Wire)
Sep-07-23 07:00AM	Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek 2023 (Business Wire)
Sep-01-23 06:51PM	Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
07:00AM	Loading…
Aug-31-23 07:00AM	Enanta Pharmaceuticals to Participate in Investor Conferences in September (Business Wire)
Aug-13-23 08:08AM	Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade (Simply Wall St.)
Aug-09-23 01:49PM	Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q3 2023 Earnings Call Transcript (Insider Monkey) -9.83%
Aug-08-23 02:23PM	Why Shares of Enanta Pharmaceuticals Are Dropping Tuesday (Motley Fool)
10:42AM	Q3 2023 Enanta Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 05:15PM	Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:07PM	Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot (AP Finance)
04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET (Business Wire)
Jul-31-23 07:00AM	Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023 (Business Wire)
Jun-21-23 08:00PM	ENTA: Lowering target price to $24.00 (Argus Research)
08:36AM	Are Options Traders Betting on a Big Move in Enanta Pharmaceuticals (ENTA) Stock? (Zacks)
Jun-20-23 07:00AM	Enanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus (Business Wire)
Jun-07-23 07:00AM	Enanta Pharmaceuticals Announces Data Presentation at the European Association for the Study of the Liver (EASL) International Liver Congress 2023 (Business Wire)
May-31-23 07:00AM	Enanta Pharmaceuticals to Participate at Jefferies Global Healthcare Conference (Business Wire)
May-11-23 05:05AM	The Petri Dish: Laronde CEO exits after 6 months; Enanta seeks Covid pill partner (American City Business Journals)
07:00AM	Loading…
May-09-23 07:00AM	Enanta Pharmaceuticals to Participate in Two Investor Conferences in May (Business Wire) -25.66%
May-08-23 05:15PM	Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:11PM	Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot (AP Finance)
04:01PM	Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19 (Business Wire)
04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET (Business Wire)
May-02-23 04:01PM	Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2023 (Business Wire) -6.69%
Apr-26-23 08:00PM	ENTA: Lowering target price to $36.00 (Argus Research)
Apr-25-23 08:01AM	Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 Million (Business Wire)
Apr-19-23 09:32AM	Enanta Pharmaceuticals (NASDAQ:ENTA) investors are sitting on a loss of 57% if they invested five years ago (Simply Wall St.)
Apr-17-23 07:00AM	Enanta Pharmaceuticals Presents Data for its COVID-19 and Respiratory Syncytial Virus Programs at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (Business Wire)
Apr-06-23 07:00AM	Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus (Business Wire)
Apr-05-23 07:00AM	Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) (Business Wire)
Mar-14-23 07:00AM	Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research (Business Wire)
Mar-08-23 08:51AM	Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research (Business Wire)
Mar-07-23 07:00AM	Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference (Business Wire)
Feb-09-23 12:58PM	Enanta Pharmaceuticals First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
Feb-08-23 02:13PM	Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2023 Earnings Call Transcript (Insider Monkey)
12:57PM	These Analysts Just Made A Huge Downgrade To Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) EPS Forecasts (Simply Wall St.)
Feb-07-23 05:15PM	Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET (Business Wire)
07:00AM	Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference (Business Wire)
Jan-31-23 07:00AM	Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022 (Business Wire)
Jan-06-23 07:00AM	Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire) +6.78%
05:29AM	An Intrinsic Calculation For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Suggests It's 49% Undervalued (Simply Wall St.)
Jan-03-23 07:00AM	Enanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-25-22 12:07PM	Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Nov-23-22 05:09AM	Newsflash: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Analysts Have Been Trimming Their Revenue Forecasts (Simply Wall St.)
Nov-22-22 07:00AM	Enanta Pharmaceuticals to Participate in Two Investor Conferences in November (Business Wire)
Nov-21-22 05:15PM	Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:02PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET (Business Wire)
Nov-14-22 07:00AM	Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Fourth Quarter and Full Year Ended September 30, 2022 (Business Wire)
Nov-09-22 07:00AM	Enanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 (Business Wire)
Nov-03-22 11:22AM	Investors in Enanta Pharmaceuticals (NASDAQ:ENTA) have unfortunately lost 51% over the last year (Simply Wall St.)
Oct-19-22 08:00AM	Enanta Pharmaceuticals Presents New Preclinical Data for EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 at IDWeek 2022 (Business Wire)
Oct-17-22 07:00AM	Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus (Business Wire)
Oct-07-22 01:57PM	10 Best Pharmaceutical Stocks to Buy According to Steven Boyds Armistice Capital (Insider Monkey) -5.96%
Oct-03-22 07:00AM	Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus (Business Wire)
Sep-29-22 07:00AM	Enanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV Symposium (Business Wire)
Sep-22-22 07:01AM	Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposium (Business Wire)
Sep-07-22 08:30AM	New Preclinical Data for EDP-235, Enantas Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek 2022 (Business Wire)
Sep-01-22 07:00AM	Enanta Pharmaceuticals to Participate in Two Investor Conferences in September (Business Wire) +6.03%
Aug-14-22 08:27AM	Need To Know: Analysts Just Made A Substantial Cut To Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Estimates (Simply Wall St.)
Aug-11-22 10:55AM	The Petri Dish: Cyteir puts a drug on pause, Alexion vet joins Watertown biotech (American City Business Journals)
Aug-09-22 12:00AM	Enanta Pharmaceuticals (ENTA) Q3 2022 Earnings Call Transcript (Motley Fool)
Aug-08-22 05:55PM	Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:03PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET (Business Wire)
04:00PM	Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer (Business Wire)
Aug-02-22 10:00AM	MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Aug-01-22 07:00AM	Enanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022 (Business Wire) +8.21%
Jul-29-22 07:40AM	Enanta's COVID-19 Treatment Shows Favorable Action In Healthy Participants (Benzinga) +10.97%
07:00AM	Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19 (Business Wire)
Jul-28-22 10:03AM	Earnings Preview: Enanta Pharmaceuticals (ENTA) Q3 Earnings Expected to Decline (Zacks)
Jul-01-22 09:41AM	Enanta Pharmaceuticals Bounces Off a Key Support Level Once Again (TheStreet.com)
Jun-27-22 11:42AM	Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt Sensibly? (Simply Wall St.)
Jun-24-22 09:03AM	Enanta Pharmaceuticals (ENTA) Stock Jumps 10.1%: Will It Continue to Soar? (Zacks)
Jun-23-22 10:28AM	Cases climb in Southeast Asia and Europe in latest week as BA.4 and BA.5 subvariants take hold (MarketWatch) +10.07%
07:46AM	Enanta Pharmaceuticals, which is developing its own COVID-19 antiviral, says Pfizer infringed on a patent with Paxlovid (MarketWatch)
Jun-22-22 04:03PM	Enanta Pharmaceuticals Sues Pfizer Over Blockbuster Covid Pill Paxlovid (Investor's Business Daily)
02:14PM	Enanta Pharmaceuticals sues Pfizer for patent infringement involving Paxlovid (American City Business Journals)
Jun-21-22 04:50PM	Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer (Business Wire)
Jun-08-22 07:00AM	Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress 2022 (Business Wire)
Jun-02-22 07:00AM	Enanta Pharmaceuticals to Participate in Two Investor Conferences in June (Business Wire)
May-25-22 06:12AM	Biotech signs new lease in Alexandrias Watertown mega campus (American City Business Journals)
May-19-22 03:02PM	Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops (Zacks)
09:07AM	Enanta's stock is down after its experimental RSV treatment failed in a mid-stage clinical trial (MarketWatch)
May-18-22 04:01PM	Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV) (Business Wire) -6.24%
May-12-22 12:27PM	Swelling losses haven't held back gains for Enanta Pharmaceuticals (NASDAQ:ENTA) shareholders since they're up 61% over 5 years (Simply Wall St.)
May-10-22 02:11AM	Enanta Pharmaceuticals (ENTA) Q2 2022 Earnings Call Transcript (Motley Fool) +6.52%
May-09-22 05:45PM	Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -7.88%
04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET (Business Wire)

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gardiner Nathaniel S.	Sr. VP & General Counsel	Apr 18	Option Exercise	30.00	6,667	200,010	79,980	Apr 19 07:25 PM
Vance Terry	Director	Mar 16	Option Exercise	14.00	5,800	81,200	21,095	Mar 17 06:46 PM
Or Yat Sun	Sr. VP & CSO	Mar 15	Option Exercise	14.00	13,925	194,950	388,627	Mar 17 06:37 PM
MELLETT PAUL J	Treasurer and CFO	Mar 15	Option Exercise	14.00	10,440	146,160	107,996	Mar 17 06:41 PM
Or Yat Sun	Sr. VP & CSO	Mar 15	Sale	44.45	13,925	618,960	374,702	Mar 17 06:37 PM
MELLETT PAUL J	Treasurer and CFO	Mar 15	Sale	44.43	10,440	463,802	97,556	Mar 17 06:41 PM
Luly Jay R.	President and CEO	Mar 13	Option Exercise	14.00	27,912	390,768	847,722	Mar 14 06:26 PM
Luly Jay R.	President and CEO	Mar 13	Sale	45.16	27,912	1,260,628	819,810	Mar 14 06:26 PM
MELLETT PAUL J	Treasurer and CFO	Feb 09	Sale	53.76	5,000	268,816	83,463	Feb 13 07:58 PM
MELLETT PAUL J	Treasurer and CFO	Jan 09	Option Exercise	14.18	2,812	39,874	88,463	Jan 10 07:11 PM
Luly Jay R.	President and CEO	Dec 19	Option Exercise	27.58	14,500	399,910	788,305	Dec 19 07:50 PM
MELLETT PAUL J	Treasurer and CFO	Dec 19	Option Exercise	14.18	4,148	58,819	85,651	Dec 19 07:53 PM
Luly Jay R.	President and CEO	Dec 16	Option Exercise	14.10	30,000	422,907	803,805	Dec 16 09:44 PM
Luly Jay R.	President and CEO	Dec 16	Sale	44.72	30,000	1,341,713	773,805	Dec 16 09:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ENTA

Enanta Pharmaceuticals Inc

Upgrade your FINVIZ experience